1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Themis Medicare Limited

Themis Medicare Limited

THEMISMED.NS
Themis Medicare LimitedIN flagNational Stock Exchange of India
116.05
INR
+4.17
- -
10.69BMarket Cap
Themis Medicare Limited
THEMISMED.NS
(National Stock Exchange of India)

Recent

price

116.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
31.31
19.59
21.55
23.08
23.84
27.3
23.75
22.72
19.89
21.82
24.96
42.54
37.43
40.92
44.04
- -
37.06
Revenue per Share
1.42
-4.03
-0.78
0.32
0.73
1.91
1.77
1.23
-1.17
2.7
3.89
7.92
6.18
4.73
3.24
- -
0.12
Basic EPS, GAAP
-1.01
-3.39
0.22
0.09
1.51
2.09
-0.77
-0.19
0.58
-0.6
4.24
1.5
-1.38
0.4
2.09
- -
- -
Free Cash Flow per Basic Share
0.3
0.09
0.09
0.09
0.18
0.18
- -
- -
- -
- -
0.17
0.43
0.5
0.5
0.5
- -
- -
Dividend per Share
1
1
1
1
1
1
2.02
3.28
2.14
4.88
8.81
16.31
22
26.2
28.94
- -
1
Book Value per Share
11.35
7.25
6.46
6.67
6.97
12.54
16.63
18.19
17.04
19.76
23.65
31.14
36.8
40.97
43.69
- -
43.15
Tangible Book Value per Share
81
81
81
85
85
85
90
92
92
92
92
92
92
92
92
- -
92
Basic Weighted Avg Shares
2,521
1,577
1,735
1,951
2,019
2,324
2,147
2,086
1,826
2,004
2,293
3,913
3,445
3,766
4,055
3,422
3,422
Sales/Revenue/Turnover
8.55
-13.01
4.55
7.54
8.22
15.2
11.99
8.54
-3.12
13.7
17.85
22.01
16.54
10.42
9.65
-2.9
-2.9
Operating Margin (%)
77
77
89
94
115
119
75
74
80
83
85
95
105
122
99
103
103
Depreciation Expense
114
-325
-63
27
62
163
160
113
-107
248
357
729
569
435
298
11
11
Net Income, GAAP
- -
- -
- -
32.23
- -
11.16
9.13
0.9
- -
7.79
13.62
23.49
21.53
18.56
24.81
40.69
40.69
Effective Tax Rate (%)
4.52
-20.59
-3.64
1.38
3.08
7
7.43
5.41
-5.88
12.36
15.57
18.62
16.52
11.56
7.36
0.33
0.33
Profit Margin (%)
95
-209
35
-27
-21
-297
2
181
32
257
572
1,046
1,254
1,402
1,477
1,388
1,388
Working Capital
609
649
918
768
746
283
124
115
94
121
234
243
284
268
186
219
219
LT Debt
916
585
522
565
592
1,091
1,524
1,688
1,581
1,830
2,185
2,875
3,394
3,777
4,026
3,986
3,986
Total Equity
- -
- -
- -
5.24
- -
16.15
11.14
7.54
- -
9.67
12
19.48
11.03
6.94
6.04
-1.19
-1.19
Return on Invested Capital (%)
- -
- -
- -
8.36
- -
21.79
27.7
22.34
- -
28.42
28.88
39.15
24.08
15.74
10.89
3.26
3.26
Return on Capital (%)
141.62
-403.34
-78.47
32.68
73.44
191.68
119.07
46.65
-43.16
76.84
56.78
63.11
32.28
19.62
11.75
0.83
0.83
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
780
- -
782
LT Borrowings
176
- -
219
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
- -
92
Market Capitalization
12,255
9,276
6,101

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,990
- -
3,050
Cash, Cash Equivalents & STI
190
- -
156
Accounts Receivable, Net
1,734
- -
1,781
Inventories
764
- -
811
Total Current Liabilities
1,739
- -
1,662
Payables & Accruals
- -
- -
- -
ST Debt
780
- -
782
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.58%
13.3%
-1%
Free Cash Flow
-173.36%
-20.63%
-142.19%
Net Income, GAAP
-58.19%
-13.79%
-96.17%
Sales/Revenue/Turnover
6.13%
12.02%
-15.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
966
1,048
825
927
3,766
2025
1,230
1,170
938
717
4,055
2026
976
780
901
765
3,422

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.98
1.23
0.8
- -
4.73
2025
2.68
1.55
0.06
-1.05
3.24
2026
-1.54
-0.39
1.1
0.96
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.5
2026
- -
- -
- -
- -
- -
Similar Companies
Shionogi & Co., Ltd. (SGIOF)
Avivagen Inc. (VIVXF)
Caplin Point Laboratories Ltd. (CAPLIPOINT.BO)
North China Pharmaceutical Company Ltd. (600812.SS)
Zydus Lifesciences Limited (ZYDUSLIFE.BO)
Akums Drugs & Pharmaceuticals Ltd. (AKUMS.NS)
Business
Themis Medicare Limited operates as a pharmaceutical enterprise, engaging in the development and global distribution of medicinal products. The company focuses on manufacturing both active pharmaceutical ingredients and a diverse range of finished formulations, addressing critical needs across several therapeutic segments including anti-infective, antimalarial, anti-tuberculosis, cardiology, general health and nutrition, oncology, ophthalmology, and pain management. Known for its innovative approach, Themis Medicare utilizes patented platform technologies to create differentiated parenteral formulations and advanced drug delivery systems, such as the patented ETOJET, a pioneering Etoricoxib injectable, and EMAL, an indigenous once-daily antimalarial. The firm was established in 1969, initially as Themis Chemicals, before adopting its current name in 2001, and maintains its primary operational base in Mumbai, India. While expanding its presence to over 44 countries, Themis Medicare has also recently reported a consolidated net loss of ₹3.62 crores for the second quarter of fiscal year 2026, alongside a 33.35% year-on-year decline in net sales to ₹77.99 crores. The company continues to advance its robust research and development pipeline, with 31 new drug delivery system projects in progress, and aims to strengthen its position in the hospital business sector.